Galectin Therapeutics (GALT) Long-Term Debt Issuances (2021)
Galectin Therapeutics' (GALT) quarterly Long-Term Debt Issuances came in at $10.0 million in Q4 2021, little changed quarter-over-quarter from $10.0 million in Q3 2021.
Galectin Therapeutics (GALT) Long-Term Debt Issuances (2021) Analysis & Trends
Galectin Therapeutics' Long-Term Debt Issuances history runs 1 years deep, the most recent figure standing at $10.0 million for Q4 2021.
- On a quarterly basis, Long-Term Debt Issuances changed N/A year-over-year to $10.0 million in Q4 2021; TTM through Dec 2022 was $20.0 million, a N/A change from a year earlier, with the FY2021 full-year figure at $30.0 million, changed N/A from the prior year.
- Long-Term Debt Issuances steadied at $10.0 million in Q4 2021 per GALT's latest filing, from $10.0 million in the prior quarter.
- Across five years, Long-Term Debt Issuances topped out at $10.0 million in Q3 2021 and bottomed at $10.0 million in Q3 2021.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Debt Issuances (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Galectin Therapeutics | 227.21 Mn | 227.21 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 10.00 Mn |
| Dec 31, 2021 | 10.00 Mn |
| Sep 30, 2021 | 10.00 Mn |
| Sep 30, 2021 | 10.00 Mn |